Amylin Pharmaceuticals (AMLN) Posts Narrower than Expected Q1 Loss of 23c/Share

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.23), $0.06 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $153.7 million versus the consensus estimate of $161.66 million.

For earnings history and earnings-related data on Amylin Pharmaceuticals, Inc. (AMLN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat